EP1283 Preliminary experience in the use of J-Plasma device in gynecological malignancies. (1st November 2019)

• Record Type: Journal Article
• Authors: Gueli Alletti, S; Rosati, A; Capozzi, VA; Costantini, B; Vizzielli, G; Fagotti, A; Fanfani, F; Fedele, C; Cianci, S; Scambia, G
• Is Part Of: International journal of gynecological cancer. Volume 29(2019)Supplement 4
• Page Start: A646
• Page End: A646
• Publication Date: 2019-11-01
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2019-ESGO.1289
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction/Background: The present study investigated the role of this novel plasma energy device in gynecological malignancies in the context of a modern personalized approach delivered by a tertiary care referral center. The indication was the resection/ablation of peritoneal and/or serosal carcinomatosis, either in laparotomy or in laparoscopy. Methodology: From January 2019 to April 2019 six patients, referring to the Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome, were selected for a feasibility study on the use of J-Plasma in advanced gynecological cancer conditions. The setting of the device used was Coagulation 45, Cut 45, Bipolar Macro 1, J-Plasma Power 40%, Gas Flow 4.0 l/min, Pulsing 80. Results: All patients showed peritoneal/serosal carcinomatosis with an indication of regional peritonectomy and/or ablation respectively. Three patients underwent laparoscopic cytoreduction (Group 1= for interval debulking surgery (n=2) and stage IV endometrial cancer (n=1). Three patients underwent laparotomic primary debulking surgery for advanced ovarian cancer (Group 2). All patients achieved optimal residual tumor at the end of surgery. The device was used for parietal, diaphragmatic, and mesenteric peritonectomy and to ablate nodules on the bowel serosa. The median OT and median EBL were 195 min and 100 ml for Group 1, and 420 min and 500 ml for Group 2. The median hospital stay was 4 days for Group 1 and 13 days Group 2 respectively. No intra- and post-operative complications were registered within 60 days after surgery. Conclusion: The use of J-PLASMA in the laparoscopic or laparotomic cytoreductive surgery could enhance the removal of peritoneal and serosal carcinomatosis. This kind of energy seems to be safe in performing peritoneal stripping and serosal ablation without increasing the morbidity. Further experience and a longer follow-up period are required to establish the use of the J-PLASMA in cytoreductive surgery for gynecological cancer. Disclosure: Nothing to disclose